Semaglutide vs Tesamorelin
A comprehensive, data-driven comparison of Semaglutide (Ozempic) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Semaglutide Ozempic, Wegovy | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | FDA Approved | FDA Approved |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Type 2 diabetes, chronic weight management, and MASH | HIV-associated lipodystrophy |
| Weight Loss % | 15% | N/A |
| Monthly Cost | $1,000 - $1,400/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2.4mg weekly (Wegovy dose) | 2mg daily |
| Frequency | Weekly | Daily |
| Mechanism | GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Approved | Approved |
Key Differences
- 1Semaglutide has clinical weight loss data (15%), while Tesamorelin is not primarily indicated for weight loss.
- 2Tesamorelin is generally more affordable ($200 - $1,500/mo) compared to Semaglutide ($1,000 - $1,400/mo).
- 3Semaglutide is dosed weekly, while Tesamorelin is daily.
- 4They belong to different categories: Semaglutide (Weight Loss) vs Tesamorelin (Growth Hormone).
Which Is Better For...
Tesamorelin
More budget-friendly option with lower monthly costs
Semaglutide
More convenient dosing schedule (weekly)
Tesamorelin
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Semaglutide | $1,000 - $1,400/mo | FDA Approved | Novo Nordisk |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
Semaglutide has demonstrated 15% average weight loss in clinical trials. Tesamorelin is not primarily used for weight loss.
Semaglutide typically costs $1,000 - $1,400/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Semaglutide is FDA-approved. Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. In August 2025, it received accelerated approval for MASH (metab...
View Full Semaglutide GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Semaglutide and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.